Kleinrok Z, Chmielewska B, Chibowski D, Siezieniewska Z, Rajtar G, Sawiniec Z
Department of Pharmacology, School of Medicine, Lublin.
Acta Physiol Pol. 1987 Sep-Oct;38(5):386-401.
The effect of two newly synthesized 5-amino modified analogues of rubidomycine was submitted to preliminary pharmacological and histological investigations in healthy Albino Swiss mice. The results showed a similarity of the tested properties of the new compounds and commercial rubidomycine, suggesting the same spectrum undesired side-effects after acute administration. Of the two novel compounds DR-22 was found to be less toxic, while much potent in its action on the haematopoietic system in comparison to rubidomycine, in prolonged treatment. DR-22 is a candidate for further, more detailed investigations.
在健康的瑞士白化小鼠中，对两种新合成的5-氨基修饰的柔红霉素类似物的效果进行了初步药理和组织学研究。结果表明，新化合物与市售柔红霉素的测试特性相似，表明急性给药后有相同范围的不良副作用。在这两种新化合物中，发现DR-22毒性较小，而与柔红霉素相比，在长期治疗中对造血系统的作用更强。DR-22是进一步进行更详细研究的候选药物。
